News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
94,245 Results
Type
Article (6886)
Company Profile (40)
Press Release (87319)
Multimedia
Podcasts (7)
Webinars (1)
Section
Business (28096)
Career Advice (128)
Deals (4059)
Drug Delivery (33)
Drug Development (14176)
Employer Resources (12)
FDA (2876)
Job Trends (2128)
News (49752)
Policy (6076)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (430)
Accelerated approval (3)
Adcomms (7)
Allergies (33)
Alliances (9138)
ALS (13)
Alzheimer's disease (265)
Antibody-drug conjugate (ADC) (47)
Approvals (2875)
Artificial intelligence (46)
Autoimmune disease (9)
Automation (3)
Bankruptcy (19)
Best Places to Work (1804)
BIOSECURE Act (18)
Biosimilars (78)
Biotechnology (27)
Bladder cancer (25)
Brain cancer (6)
Breast cancer (53)
Cancer (487)
Cardiovascular disease (22)
Career advice (112)
Career pathing (3)
CAR-T (23)
Cell therapy (89)
Cervical cancer (3)
Clinical research (11586)
Collaboration (201)
Compensation (45)
Complete response letters (9)
COVID-19 (545)
CRISPR (6)
C-suite (54)
Cystic fibrosis (13)
Data (461)
Denatured (2)
Depression (6)
Diabetes (38)
Diagnostics (570)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (26)
Drug pricing (26)
Drug shortages (1)
Duchenne muscular dystrophy (28)
Earnings (9623)
Editorial (6)
Employer branding (3)
Employer resources (10)
Events (12026)
Executive appointments (128)
FDA (3232)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (150)
Gene editing (25)
Generative AI (6)
Gene therapy (88)
GLP-1 (112)
Government (1332)
Grass and pollen (1)
Guidances (13)
Healthcare (1964)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (43)
Indications (10)
Infectious disease (581)
Inflammatory bowel disease (49)
Inflation Reduction Act (4)
Influenza (15)
Intellectual property (13)
Interviews (11)
IPO (1858)
IRA (14)
Job creations (393)
Job search strategy (108)
Kidney cancer (2)
Labor market (2)
Layoffs (56)
Leadership (1)
Legal (568)
Liver cancer (13)
Lung cancer (79)
Lymphoma (30)
Machine learning (1)
Management (2)
Manufacturing (121)
MASH (13)
Medical device (1181)
Medtech (1182)
Mergers & acquisitions (2301)
Metabolic disorders (90)
Multiple sclerosis (18)
NASH (3)
Neurodegenerative disease (18)
Neuropsychiatric disorders (1)
Neuroscience (341)
NextGen: Class of 2025 (707)
Non-profit (351)
Northern California (498)
Now hiring (11)
Obesity (33)
Opinion (50)
Ovarian cancer (20)
Pain (9)
Pancreatic cancer (13)
Parkinson's disease (9)
Partnered (3)
Patents (32)
Patient recruitment (19)
Peanut (21)
People (8099)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase I (3827)
Phase II (4817)
Phase III (4242)
Pipeline (319)
Policy (57)
Postmarket research (297)
Preclinical (1499)
Press Release (66)
Prostate cancer (19)
Psychedelics (5)
Radiopharmaceuticals (37)
Rare diseases (73)
Real estate (959)
Recruiting (4)
Regulatory (4835)
Reports (11)
Research institute (387)
Resumes & cover letters (11)
RNA editing (1)
RSV (11)
Schizophrenia (11)
Series A (35)
Series B (13)
Service/supplier (3)
Sickle cell disease (7)
Southern California (504)
Special edition (3)
Spinal muscular atrophy (21)
Sponsored (9)
Startups (599)
State (1)
Stomach cancer (3)
Supply chain (12)
Tariffs (12)
The Weekly (5)
United States (4310)
Vaccines (190)
Venture capitalists (6)
Weight loss (16)
Women's health (3)
Date
Today (21)
Last 7 days (149)
Last 30 days (507)
Last 365 days (6289)
2025 (2116)
2024 (6560)
2023 (7013)
2022 (9138)
2021 (9554)
2020 (8235)
2019 (5900)
2018 (4586)
2017 (5125)
2016 (4673)
2015 (5356)
2014 (3763)
2013 (2946)
2012 (3015)
2011 (3176)
2010 (2615)
Location
Africa (93)
Alabama (11)
Alaska (1)
Arizona (12)
Arkansas (2)
Asia (8078)
Australia (886)
California (1192)
Canada (246)
China (190)
Colorado (33)
Connecticut (27)
Delaware (45)
Europe (13976)
Florida (146)
Georgia (19)
Idaho (13)
Illinois (55)
India (12)
Indiana (41)
Iowa (2)
Japan (30)
Kansas (4)
Kentucky (9)
Louisiana (2)
Maine (5)
Maryland (323)
Massachusetts (826)
Michigan (25)
Minnesota (48)
Mississippi (1)
Missouri (15)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (467)
New Mexico (4)
New York (339)
North Carolina (203)
North Dakota (8)
Northern California (498)
Ohio (40)
Oklahoma (7)
Oregon (3)
Pennsylvania (196)
Puerto Rico (1)
Rhode Island (5)
South America (136)
South Carolina (2)
Southern California (504)
Tennessee (3)
Texas (159)
Utah (25)
Virginia (18)
Washington D.C. (6)
Washington State (94)
Wisconsin (8)
94,245 Results for "wuxi biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Merck Snaps Up WuXi Biologics Facility in Ireland for $500M
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.
January 6, 2025
·
1 min read
·
Annalee Armstrong
BIOSECURE Act
WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow
WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.
October 8, 2024
·
5 min read
·
Ben Hargreaves
Press Releases
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
April 18, 2025
·
3 min read
Press Releases
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
February 27, 2025
·
2 min read
Press Releases
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
March 25, 2025
·
14 min read
China
WuXi Biologics Takes Net Profit Hit Despite Inking Record Number of New Projects
With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.
August 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Insights from Chris Chen, the CEO of WuXi Biologics: How Quality Assurance and Technology Has Evolved in the Biopharmaceutical CDMO Industry
April 9, 2025
·
1 min read
Press Releases
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
March 3, 2025
·
3 min read
BIOSECURE Act
WuXi Mulls Sale of Some US, European Operations: FT
The
Financial Times
reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of its production sites in Europe.
October 3, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
January 7, 2025
·
3 min read
1 of 9,425
Next
